Literature DB >> 20179165

Risks to health professionals from hazardous drugs in Japan: a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide.

Shin-ichi Sugiura1, Mika Asano, Kuninori Kinoshita, Manabu Tanimura, Toshitaka Nabeshima.   

Abstract

PURPOSE: In Japan, concerns exist regarding the dangers inherent when handling cytotoxic drugs, particularly drugs such as 5-FU, Thiotepa, Cytarabine, Tegaful, and Sizofiran which are contained in ampoules or vials, since nurses and medical doctors have been preparing these cytotoxic drugs in the open spaces of wards in the absence of appropriate garments and personal protective equipment. In addition, the administration tubes for these dangerous drugs have been exchanged at the patients' bedside, typically in rooms shared by several patients. To gain insight into the severity of the occupational hazards posed by these practices, we conducted a pilot study of environmental and biological monitoring of occupational exposure to cyclophosphamide (CP).
SETTING: At Nagoya University Hospital, Nagoya, Japan, in February 2006, two departments, A and B, were monitored with surface-wipe, and urine samples were analyzed using the Sessink method (exposure control, The Netherlands). Department A had a preparation room with biological safety cabinet (BSC) where the pharmacists prepare cytotoxic drugs. Department B did not have a BSC.
RESULTS: Many areas of the treatment rooms were contaminated with CP. CP was detected on tables and telephone stands where cytotoxic drugs were not used as well as tables used to prepare cytotoxic drugs. Significant differences in CP concentrations were detected from the urine of two of the three nurses who cared for the same patients without gloves. The nurses rotated and inherited the patient who had the highest risk of contamination. CP was detected only once from the urine of the medical doctor who prepared CP. He was not wearing any PPE other than gloves. All of the pharmacists wearing PPE were free from contamination of CP. DISCUSSION: Regardless of the use of BSC, wards were contaminated with CP. The contamination may not occur due to the sealing used in CP containers and administration tubes when discarding them. CP was detected only once in the urine of a medical doctor who prepared CP by warming it. The cause may be inhalation of CP gas from the injector. The contamination of the nurses may be from dermal absorption because absorption continued even after the shift ended and the nurses left the facility. CP was not detected in pharmacists who followed the guidelines for preparation of CP. All of the medical staff should follow the guidelines when they handle CP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20179165     DOI: 10.1177/1078155209358632

Source DB:  PubMed          Journal:  J Oncol Pharm Pract        ISSN: 1078-1552            Impact factor:   1.809


  10 in total

1.  Hazardous drug residue on exterior vial surfaces: evaluation of a commercial manufacturing process.

Authors:  Luci A Power; Paul J M Sessink; Kathy Gesy; Flay Charbonneau
Journal:  Hosp Pharm       Date:  2014-04

2.  Environmental contamination with hazardous drugs in quebec hospitals.

Authors:  Jean-François Bussières; Cynthia Tanguay; Karine Touzin; Eric Langlois; Michel Lefebvre
Journal:  Can J Hosp Pharm       Date:  2012-11

3.  Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals.

Authors:  Susana Viegas; Mário Pádua; Ana Costa Veiga; Elisabete Carolino; Mário Gomes
Journal:  Environ Monit Assess       Date:  2014-08-06       Impact factor: 2.513

4.  Antineoplastic drug contamination in the urine of Canadian healthcare workers.

Authors:  Chun-Yip Hon; Kay Teschke; Hui Shen; Paul A Demers; Scott Venners
Journal:  Int Arch Occup Environ Health       Date:  2015-01-28       Impact factor: 3.015

Review 5. 

Authors:  Céline Poupeau; Christel Roland; Jean-François Bussières
Journal:  Can J Hosp Pharm       Date:  2016-10-31

6.  Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.

Authors:  Paul J M Sessink; Jason Trahan; Joseph W Coyne
Journal:  Hosp Pharm       Date:  2013-03

7.  The assessment of environmental and external cross-contamination in preparing ready-to-administer cytotoxic drugs: a comparison between a robotic system and conventional manual production.

Authors:  Annabel Werumeus Buning; Tjerk H Geersing; Mirjam Crul
Journal:  Int J Pharm Pract       Date:  2019-09-06

8.  Environmental assessment of cytotoxic drugs in the Oncology Center of Cyprus.

Authors:  Elpidoforos S Soteriades; Sofia C Economidou; Artemis Tsivitanidou; Petros Polyviou; Amanda Lorimer; Nikos Katodritis; Stavroula Theophanous-Kitiri
Journal:  PLoS One       Date:  2020-03-05       Impact factor: 3.240

Review 9.  Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.

Authors:  Kurinchi Selvan Gurusamy; Lawrence Mj Best; Cynthia Tanguay; Elaine Lennan; Mika Korva; Jean-François Bussières
Journal:  Cochrane Database Syst Rev       Date:  2018-03-27

10.  Occupational risks evaluation in a centralized antineoplastic agent preparation unit.

Authors:  Quentin Dubray; Taibou Diallo; Richard Loeuillet; Emilie Andre; Anne-Sophie Fauqueur; Sandrine Poil; Nathalie Thromas; Philippe-Henri Secretan; Salvatore Cisternino; Joël Schlatter
Journal:  SAGE Open Med       Date:  2019-07-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.